Cali Organics EU
The Master Catalogue
BloomBridge × SOMAÍ Pharmaceuticals
Confidential — April 2026
The European pharmaceutical cannabis market is valued at €3.2 billion today and projected to surpass €30 billion within a decade. No single company controls the entire value chain.
Cali Organics EU changes that. Built on 25+ years of proprietary genetics, a proven production system, and institutional-grade compliance infrastructure — this is the first platform in Europe that owns everything from seed genetics to finished brand.
Trichome inspection — Pharmaceutical-grade cultivation
The legendary genetics that defined California cannabis culture and continue to shape the global industry. Each strain in our genetic library represents decades of careful breeding, selection, and preservation of the most sought-after cannabis genetics.
The first-ever isolation of cannabis terpenes — an innovation sparked by Kenny, supported by Rick Doblin, and guided by the legendary Sasha Shulgin himself. This breakthrough laid the scientific foundation for understanding the therapeutic power of terpene profiles in medical cannabis.
What makes Cali Organics EU unprecedented is not any single capability — it is the integration of all five into one vertically controlled system.
25+ years of elite strain development from California's legendary OG and Kush lineages.
Proprietary cultivation protocols producing at $0.15–$0.30 per gram.
Pharmaceutical-grade manufacturing through SOMAÍ's certified facility.
The first premium cannabis brand built for European institutions.
Institutional-grade traceability and audit infrastructure built for regulators.
| Metric | Year 1 | Year 3 | Year 5 | 5-Yr Total |
|---|---|---|---|---|
| Revenue | $15.8M | $28.9M | $50.6M | $155.4M |
| EBITDA | $12.1M | $23.2M | $41.0M | $124.8M |
| Net Income | $9.0M | $17.9M | $32.2M | $96.4M |
| Metric | Cali Organics | Industry |
|---|---|---|
| Production Cost | $0.40/g | $0.45/g |
| Selling Price | $1.00+/g | Varies |
| Gross Margin | 90% | 55–60% |
| LTV:CAC Ratio | 23–41:1 | 3–5:1 |
| 5-Year ROI | 372% | > 100% |
| IRR | 50.38% | > 20% |
A new 28,000 m² cultivation campus — separate from SOMAÍ's existing operations — engineered from the ground up for pharmaceutical-grade organic production with staged expansion to 79,971 m² by Year 5.
8–12 months. GMP-compliant contractors, environmental control systems.
12–18 months. QMS implementation, SOPs, third-party certification.
8 tonnes Year 1, scaling 30% annually to 23 tonnes.
Our research is led by pioneers who have shaped the global regulatory and scientific landscape for cannabis medicine.
Cali Organics, powered by BloomBridge's proprietary space research program, is breaking new ground — literally beyond Earth. Together with our global partners, we are sending cannabis seeds and plant genetics into low-Earth orbit to study how cosmic radiation, microgravity, and extreme environments influence plant development.
Studying the effects of cosmic radiation, microgravity, and extreme environments on cannabis genetics and plant development.
First launch completed June 2025. Cannabis seeds and plant genetics sent to the International Space Station corridor.
No other cannabis company operates a space research program. This positions BloomBridge at the frontier of genetic science and therapeutic innovation.
No other company in Europe — or globally — controls all seven dimensions of the cannabis value chain simultaneously.
| Company | Genetics | Production IP | Organic | EU-GMP | Brand | Compliance | Cost Adv. |
|---|---|---|---|---|---|---|---|
| Tilray | — | — | — | Yes | — | Partial | — |
| Aurora | — | — | — | Yes | — | Partial | — |
| Canopy Growth | — | — | — | Yes | — | Partial | — |
| Curaleaf | — | — | — | — | — | — | — |
| Intercure | — | — | — | Yes | Partial | Yes | — |
| SOMAÍ (standalone) | — | — | — | Yes | — | Yes | — |
| Cali Organics EU | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Invisible to the consumer. Indispensable to regulators and investors. Full traceability across cultivation, manufacturing, and clinical research.
Full production lifecycle visibility from seed to sale.
EU-GMP data integrity standards met across all records.
Anti-diversion controls built for international export.
Government-facing dashboard always prepared.
Market entry via established distribution partners across England, Germany, and Israel. GMP/GDP/CQC/MHRA aligned channels. 100% export revenue through contracted LOIs.
France, Italy, Spain, Netherlands. Premium medical product lines. Revenue target: $18–25M annually.
Full European coverage plus Middle East. Premium wholesale ($2.00/gram). Brand licensing.
LOIs secured at $1.00–$1.50/gram. Revenue certainty from Day 1.
| Method | Low | Mid | High |
|---|---|---|---|
| DCF Analysis | $95M | $97M | $100M |
| Comparable Companies | $150M | $243M | $337M |
| Precedent Transactions | $146M | $249M | $352M |
| Weighted Average | $130M | $197M | $263M |
The first company to control genetics, production, and brand in Europe will define the industry for the next 30 years.
